Leading Companies

Inflamalps SA

Tens of millions of patients suffer from dry eye. Inflamalps is developing INF101, for the topical treatment of dry eye. INF101 was shown to have an efficacy comparable to cyclosporine A the gold standard therapy in dry eye. INF101 could thus become one of the leading therapies in this indication.

Inflamalps SA

Route de l'Ile-au-Bois 1A
1870 Monthey
Switzerland


산업 부문
Chemical & Pharmaceutical Technology
Bio Technology (Biotech)
Life Science
자세한 정보
우리를 추천해 주세요